---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-23-000035"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2023-05-23T23:59:59+00:00"
generated_at: "2026-06-14T17:45:44.524921+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences initiates global product recall due to endotoxin issues, cuts guidance

## Summary
- Voluntary recall of SurgiMend, PriMatrix, Revize, TissueMend from Boston facility (March 2018 – May 2023).
- Expects $22M inventory impairment charge in Q2 ending June 30, 2023; no cash impact.
- Q2 2023 guidance revised: revenue $372M-$376M, adjusted EPS $0.55-$0.59.
- If stoppage continues through 2023, full-year revenue impact ~$60M, EPS ~$0.35.
- Boston facility products represent ~5% of consolidated revenues; manufacturing halt extended.

## SEC filing metadata
- accession: 0000917520-23-000035
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2023-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.06, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752023000035/0000917520-23-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752023000035/iart-20230522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-23-000035
- JSON: https://secwatch.observer/filing/0000917520-23-000035.json
- Plain text: https://secwatch.observer/filing/0000917520-23-000035.txt

## Key facts
- Restructurings & Charges
  INTEGRA LIFESCIENCES HOLDINGS CORP announced a impairment with charges of approximately $22 million affecting Boston, Massachusetts facility.
  - Type: impairment
  - Charge: approximately $22 million
  - Affected area: Boston, Massachusetts facility
  source text: Integra LifeSciences Holdings Corporation (the “Company”), after consultation with the U.S. Food and Drug Administration (the “FDA”), initiated a voluntary global recall of all products manufactured in its Boston, Massachusetts facility (the “Boston facility”) distributed between March 1, 2018 and May 22, 2023 (the “voluntary recall”). As a result, the Company concluded on May 22, 2023 that it expects it will incur an impairment charge related to the write-off of inventories, net, of approximately $22 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752023000035/0000917520-23-000035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.